Skip to content
Disclosery

Nextech Invest Ltd.

Follow

13F filer, CIK 1595430, Zurich, Switzerland

Nextech Invest Ltd. reported $1,421,052,380 across 17 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 95.83% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001595430-26-000005

Period
2026-03-31
Reported value
$1.42B
Holdings
17
Top 10 weight
95.83%
New
2
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CTMXnew+4,449,932$20.9M
ALMSadded+625,000$13.8M
RLAYadded+825,000$8.21M
CRVSnew+450,000$6.58M
ENGNadded+200,000$1.36M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MERSANA THERAPEUTICS INCexited-482,689-$14M
SPRYreduced-50,000-$401K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001595430-26-000005, largest first. % of portfolio is the value over $1,421,052,380, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 7,601,087 shares; 2025Q2: 7,601,087 shares; 2025Q3: 7,601,087 shares; 2025Q4: 7,601,087 shares; 2026Q1: 7,601,087 shares 7,601,087$739M52.02%0Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 4,055,861 shares; 2025Q2: 4,055,861 shares; 2025Q3: 4,055,861 shares; 2025Q4: 4,055,861 shares; 2026Q1: 4,055,861 shares 4,055,861$155M10.93%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 5,533,980 shares; 2025Q2: 5,533,980 shares; 2025Q3: 5,533,980 shares; 2025Q4: 7,266,081 shares; 2026Q1: 7,266,081 shares 7,266,081$152M10.7%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 5,285,714 shares; 2025Q2: 7,162,637 shares; 2025Q3: 7,162,637 shares; 2025Q4: 7,162,637 shares; 2026Q1: 7,162,637 shares 7,162,637$90.8M6.39%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 1,476,998 shares; 2025Q2: 2,915,998 shares; 2025Q3: 2,915,998 shares; 2025Q4: 2,915,998 shares; 2026Q1: 3,540,998 shares 3,540,998$78M5.49%+625,000Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 3,846,409 shares; 2025Q2: 3,846,409 shares; 2025Q3: 3,846,409 shares; 2025Q4: 4,701,506 shares; 2026Q1: 5,526,506 shares 5,526,506$55M3.87%+825,000Timeline
ZYMEZYMEWORKS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 1,113,946 shares; 2025Q2: 1,113,946 shares; 2025Q3: 1,113,946 shares; 2025Q4: 1,113,946 shares; 2026Q1: 1,113,946 shares 1,113,946$27.9M1.96%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: 340,909 shares; 2025Q3: 340,909 shares; 2025Q4: 278,896 shares; 2026Q1: 278,896 shares 278,896$23.2M1.63%0Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 4,449,932 shares 4,449,932$20.9M1.47%newTimeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 7,419,355 shares; 2025Q2: 7,419,355 shares; 2025Q3: 7,419,355 shares; 2025Q4: 7,419,355 shares; 2026Q1: 7,419,355 shares 7,419,355$19.4M1.37%0Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 1,141,145 shares; 2025Q2: 1,141,145 shares; 2025Q3: 1,141,145 shares; 2025Q4: 1,141,145 shares; 2026Q1: 1,141,145 shares 1,141,145$16.2M1.14%0Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,124,943 shares; 2026Q1: 2,324,943 shares 2,324,943$15.8M1.11%+200,000Timeline
CRVSCORVUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 450,000 shares 450,000$6.58M0.46%newTimeline
ARVNARVINAS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 1,408,394 shares; 2025Q2: 1,408,394 shares; 2025Q3: 1,408,394 shares; 2025Q4: 539,394 shares; 2026Q1: 539,394 shares 539,394$5.72M0.4%0Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 952,400 shares; 2025Q2: 952,400 shares; 2025Q3: 952,400 shares; 2025Q4: 952,400 shares; 2026Q1: 952,400 shares 952,400$5.02M0.35%0Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 279,237 shares; 2026Q1: 304,237 shares 304,237$5M0.35%+25,000Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not loaded; 2025Q1: 936,729 shares; 2025Q2: 741,729 shares; 2025Q3: 660,703 shares; 2025Q4: 660,703 shares; 2026Q1: 610,703 shares 610,703$4.9M0.35%-50,000Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
MERSANA THERAPEUTICS INCMERSANA THERAPEUTICS INC482,689$14Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001595430-26-000005 base2026-05-15acceptance time not in the bulk data set